D
Veracyte, Inc. VCYT
$34.09 -$0.71-2.04% NASDAQ
Recommendation
Prev Close
$34.80
Volume
598,112
Avg Vol (90D)
1,291,364
Market Cap
$2.74B
Dividend & Yield
--
52-Week Range
$22.61 - $47.32
P/E (TTM)
105.84
EPS (TTM)
$0.33
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Veracyte (VCYT): Assessing Valuation After BALANCE Trial Data and Analyst Upgrades Boost Investor Confidence
10/11/2025 - Simply Wall St
Veracyte's (VCYT) Sell (D+) Rating Reaffirmed at Weiss Ratings
10/10/2025 - MarketBeat
Veracyte (VCYT, $35.1) Moving Average Convergence Divergence (MACD) Histogram turned negative on October 8, 2025
10/9/2025 - Tickeron - Stocks
Veracyte (NASDAQ:VCYT) Upgraded to "Strong-Buy" at Zacks Research
10/8/2025 - MarketBeat
Insider Selling: Veracyte (NASDAQ:VCYT) Insider Sells 8,349 Shares of Stock
10/8/2025 - MarketBeat
Veracyte (VCYT, $34.61) RSI Indicator left the overbought zone on October 07, 2025
10/8/2025 - Tickeron - Stocks
Insider Sell: Phillip Febbo Sells Shares of Veracyte Inc (VCYT)
10/8/2025 - GuruFocus
Veracyte (NASDAQ:VCYT) Insider Sells 8,349 Shares
10/7/2025 - MarketBeat
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
10/7/2025 - Zacks Investment Research
Veracyte (VCYT, $36.04) RSI Indicator left the overbought zone on October 06, 2025
10/7/2025 - Tickeron - Technical Analysis
Will Veracyte (VCYT) Leverage PAM50 Data to Strengthen Its Position in Precision Oncology?
10/6/2025 - Simply Wall St
If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now
10/6/2025 - Zacks Investment Research
Evaluating Veracyte After Strong Quarterly Results and a 17.6% Share Price Surge
10/4/2025 - Simply Wall St
Insider Sell Alert: John Leite Sells Shares of Veracyte Inc (VCYT)
10/3/2025 - GuruFocus
A Fresh Look at Veracyte (VCYT) Valuation Following Recent 18% Share Price Rally
10/3/2025 - Simply Wall St
Veracyte (VCYT, $35.63) RSI Indicator left the overbought zone on October 02, 2025
10/3/2025 - Tickeron - Stocks
Veracyte (VCYT, $36.21) price may drop as it broke higher Bollinger Band on Oct 01, 2025
10/2/2025 - Tickeron - Stocks
Veracyte (VCYT, $36.21) RSI Indicator left the overbought zone on October 01, 2025
10/2/2025 - Tickeron - Stocks
Veracyte (VCYT, $36.21) Moving Average Convergence Divergence (MACD) Histogram turned positive on October 1, 2025
10/2/2025 - Tickeron - Stocks
Veracyte, Inc. (NASDAQ:VCYT) Given Average Recommendation of "Moderate Buy" by Analysts
10/1/2025 - MarketBeat
William Blair Reaffirms Their Buy Rating on Veracyte (VCYT)
9/30/2025 - TipRanks Financial Blog
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with ...
9/28/2025 - GuruFocus
Veracyte announces results from BALANCE trial of PAM50
9/28/2025 - TipRanks Financial Blog
Veracyte announces results from BALANCE trial of PAM50
9/28/2025 - The Fly
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
9/28/2025 - Business Wire
Income Statement
Total Revenue (TTM)
$479.13M
EBITDA (TTM)
$65.40M
EBIT (TTM)
$42.42M
Net Income (TTM)
$26.34M
Balance Sheet
Total Assets (Q)
$1.34B
Total Debt (Q)
$50.65M
Total Liabilities (Q)
$123.05M
Book Value Per Share (Q)
$15.54
Cash Flow
Cash from Operations (TTM)
$93.45M
Cash from Investing (TTM)
-$108.43M
Cash from Financing (TTM)
-$1.27M
Net Change in Cash (TTM)
-$15.85M
Filings
Filing Date
Thursday, August 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.00
7-Day Total Return
-4.32%
30-Day Total Return
12.36%
60-Day Total Return
45.00%
90-Day Total Return
24.92%
Year to Date Total Return
-15.70%
1-Year Total Return
0.21%
2-Year Total Return
52.73%
3-Year Total Return
118.67%
5-Year Total Return
-18.44%
52-week Low
Jul 18, 2025 - $22.61
52-week High
Jan 30, 2025 - $47.32
Valuation
Market Cap
$2.74B - Mid Cap
Enterprise Value
$2.47B
Price/Sales (TTM)
5.69
Price/Book (Q)
2.24
Dividends and Shares
Shares Outstanding
78.39
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.veracyte.com
Phone Number
650 243 6300
Address
6000 Shoreline Court
South San Francisco, CA 94080
Country
United States
Year Founded
2006
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate... more
NASDAQ 10/13/2025 4:00PM Eastern Quotes delayed